Investment Rating - The report maintains a "Recommended" rating for the company [1][10]. Core Views - The company has shown significant growth in both domestic and international performance, with an increase in the number of projects participated [1][9]. - The revenue for the first half of 2025 reached 178 million yuan, representing a year-over-year increase of 23.77%, while the net profit attributable to shareholders was 38 million yuan, up 55.55% year-over-year [5]. - The company’s product business, primarily focused on cell culture media, achieved a revenue of 155 million yuan, a year-over-year increase of 25.49% [9]. - The company has a growing pipeline with 282 confirmed drug development projects utilizing its media, an increase of 35 projects compared to the end of 2024 [9]. Financial Summary - The company’s total market capitalization is 6.3 billion yuan, with a circulating A-share market value of 4.3 billion yuan [1]. - The projected revenue for 2024 is 2.97 billion yuan, with a year-over-year growth of 22.3%, and net profit is expected to be 540 million yuan [7][12]. - The gross margin for the product business improved to 71.91%, while the CDMO service gross margin was -47.53% [9]. - The company’s asset-liability ratio is 8.2%, indicating a strong financial position [1].

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Group 1 - The core viewpoint of the news is that Aopumai is experiencing rapid growth in cell culture medium revenue driven by large orders and ongoing commercialization projects, with new products like transfection reagents and agarose showing promising growth despite a small base [1] - Aopumai's overseas cell culture medium business has seen a remarkable growth rate of 34.92%, primarily contributed by large clients [1] - The overall gross margin for the company is 56.84%, while the gross margin for cell culture product sales is 71.91%, indicating no significant difference in gross margins domestically and internationally when excluding CDMO business [1] Group 2 - Zhonghang Fund, established in 2016, has an asset management scale of 42.229 billion yuan, ranking 90th out of 210 in total public funds [2] - The best-performing public fund product in the past year under Zhonghang Fund is the Zhonghang Opportunity Leading Mixed Fund A, with a latest net value of 2.63 and a growth of 172.64% over the past year [2]

Group 1 - The stock price of Aopumai closed at 56.40 yuan on August 26, 2025, down by 1.87 yuan, a decrease of 3.21% from the previous trading day [1] - The trading volume on that day was 26,747 hands, with a transaction amount of 150 million yuan, and the stock experienced a fluctuation of 6.83% [1] - Aopumai is a biopharmaceutical company specializing in cell culture medium research and production, as well as contract development and manufacturing services for biopharmaceuticals [1] Group 2 - On August 26, Aopumai disclosed the results of an institutional research meeting held on August 25, where company executives discussed the operational performance for the first half of 2025, indicating significant progress despite challenges [1] - Participating institutions in the research included 10 firms such as Zhongtai Securities, CITIC Securities, and CITIC Jianzhong Securities [1] Group 3 - On August 26, the net inflow of main funds into Aopumai was 12.1482 million yuan, accounting for 0.28% of the circulating market value [1] - However, over the past five days, the overall main fund flow has shown a net outflow, totaling 27.1309 million yuan, which is 0.62% of the circulating market value [1]

Group 1 - The core viewpoint of the news is that Aopumai's stock price has declined by 5.15%, currently trading at 55.27 CNY per share, with a total market capitalization of 6.276 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The trading volume for Aopumai was 48.9595 million CNY, with a turnover rate of 1.11% [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management has increased its holdings in Aopumai by 1.2508 million shares, now holding a total of 2.9001 million shares, which accounts for 3.75% of the circulating shares [2] - The fund, ICBC Frontier Medical Stock A (001717), has a current scale of 9.33 billion CNY and has achieved a year-to-date return of 37.86%, ranking 607 out of 4222 in its category [2] - The fund manager, Zhao Bei, has been in the position for 10 years and 285 days, with the fund's best return during this period being 262.7% [2]

Group 1 - The core point of the article highlights the financing activities of Aopumai, indicating a financing buy amount of 0.19 billion yuan on August 25, ranking 1328th in the market [1] - Over the last three trading days, Aopumai has seen financing buy amounts of 0.12 billion yuan, 0.10 billion yuan, and 0.19 billion yuan respectively [1] - On the same day, the financing repayment amount was 0.42 billion yuan, resulting in a net sell of 22.95 million yuan [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day [2]

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][19]. Core Insights - The company's product business revenue grew by 26% year-on-year, with a recovery in CDMO services. In the first half of 2025, the company achieved revenue of 178 million yuan (+23.8%) and a net profit of 38 million yuan (+55.6%). The significant revenue growth is primarily attributed to strong performance in cell culture products, especially through deep collaboration with overseas clients [1][7]. - The company’s overseas business continues to show strong growth, with foreign revenue increasing by 34.9% compared to the same period last year [2][7]. - The gross margin stabilized at 56.8% (down 3.1 percentage points year-on-year), while the net margin improved to 21.1% (up 4.3 percentage points year-on-year). The overall expense ratio decreased to 31.1% (down 10.5 percentage points year-on-year) [2][14]. - The number of product pipelines reached a record high, with 282 confirmed drug development pipelines utilizing the company's cell culture products, an increase of 35 from the end of 2024 [2][17]. Financial Performance - For the first half of 2025, the company reported product sales of 155 million yuan (up 25.5% year-on-year) and CDMO service revenue of 22.27 million yuan (up 13.2% year-on-year). Product sales accounted for 87% of total revenue, remaining the core growth driver [1][7]. - The company’s profit forecasts for 2025-2027 are 78 million yuan, 112 million yuan, and 153 million yuan respectively, with corresponding P/E ratios of 82, 57, and 42 times [2][19]. - The financial projections indicate a revenue increase from 243 million yuan in 2023 to 545 million yuan in 2027, with a significant net profit recovery expected in 2025 [4][22].

金融界消息 截至2025年8月25日收盘，奥浦迈（688293）报收于58.27元，上涨4.93%，换手率3.59%， 成交量2.78万手，成交金额1.62亿元。 天眼查商业履历信息显示，上海奥浦迈生物科技股份有限公司，成立于2013年，位于上海市，是一家以 从事研究和试验发展为主的企业。企业注册资本11354.8754万人民币，实缴资本6000万人民币。公司法 定代表人为肖志华。 通过天眼查大数据分析，上海奥浦迈生物科技股份有限公司共对外投资了8家企业，参与招投标项目35 次，知识产权方面有商标信息71条，专利信息104条，此外企业还拥有行政许可65个。 来源：金融界 资金流向方面，今日主力资金净流出2653.78万元，占比成交额16.38%。其中，超大单净流出873.70万 元、占成交额5.39%，大单净流出1780.08万元、占成交额10.99%，中单净流出流入1340.91万元、占成 交额8.28%，小单净流入1312.88万元、占成交额8.1%。 奥浦迈最新一期业绩显示，截至2025中报，公司营业总收入1.78亿元、同比增长23.77%，归属净利润 3754.69万元，同比增长55.55%，扣非净利 ...

证券研究报告|公司点评报告 [Table_Title] 培养基业务延续快速增长，盈利能力呈现提升 中 [Table_Title2] 奥浦迈(688293) [Table_Summary] 事件概述 公司公告 2025 年中报：25H1 实现营业收入 1.78 亿元，同比增 长 23.77%、实现归母净利润 0.49 亿元，同比增长 62.55%、实 现扣非净利润 0.38 亿元，同比增长 55.55%。 分析判断: ► 培养基业务延续快速增长，盈利能力呈现提升中 公司 25H1 实现收入 1.78 亿元，同比增长 23.77%，其中 25Q2 单 季度实现收入 0.94 亿元，同比增长 47.2%，业绩延续快速增长趋 势。分业务来看，产品业务实现收入 1.55 亿元，同比增长 25.5%、服务业务实现收入 0.22 亿元，同比增长 13.2%，产品业 务延续快速增长趋势。25H1 归母净利润为 0.49 亿元，同比增长 62.55%，对应净利率为 20.96%，相对 24 年和 25Q1 净利率均有所 上升。展望未来，考虑到培养基业务国际化业务拓展以及国内服 务管线数量持续增长，我们判断培养基业务将呈现高速增 ...

Investment Rating - The report maintains an "Outperform" rating for the company [5][19]. Core Insights - The company's product business revenue grew by 26% year-on-year, with a recovery in CDMO services. In the first half of 2025, the company achieved revenue of 178 million yuan (+23.8%) and a net profit of 38 million yuan (+55.6%) [1][7]. - The significant revenue growth is attributed to strong performance in cell culture products, particularly through deep collaboration with overseas clients [1][7]. - The company’s overseas business continues to show robust growth, with foreign revenue increasing by 34.9% compared to the same period last year [2][7]. - The gross margin stabilized at 56.8% (down 3.1 percentage points year-on-year), while the net margin improved to 21.1% (up 4.3 percentage points year-on-year) [2][14]. - The number of product pipelines reached a record high, with 282 confirmed drug development pipelines utilizing the company's cell culture products as of the first half of 2025, an increase of 35 from the end of 2024 [2][17]. Financial Performance - For the first half of 2025, the company reported product sales of 155 million yuan (up 25.5% year-on-year) and CDMO service revenue of 22.27 million yuan (up 13.2% year-on-year) [1][7]. - The company’s revenue for Q1 and Q2 of 2025 was 84 million yuan (+5.0% year-on-year) and 94 million yuan (+47.2% year-on-year), respectively [1][7]. - The projected net profits for 2025-2027 are 78 million yuan, 112 million yuan, and 153 million yuan, respectively, with corresponding P/E ratios of 82, 57, and 42 times [2][19].